Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kathleen Cloutier

Nurse Practitioner, Adult Health Niagara Falls, NY Nurse Practitioner

NPI 1588975288 CMS profile 10604086

621 10Th St, Niagara Falls, NY 14301

Open in the dashboard

General payments

$16,665

689 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kathleen Cloutier of Niagara Falls, NY is reported in the CMS Open Payments database as having received $16,665 across 689 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,205 112
2024 General $3,800 135
2023 General $3,702 129
2022 General $3,061 163
2021 General $2,896 150

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kathleen Cloutier
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Kathleen Cloutier were reported at $3,205. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Kathleen Cloutier Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,896 $138 $43–$438 $132
2022 $3,061 $165 $54–$494 $149
2023 $3,702 $178 $61–$549 $160
2024 $3,800 $186 $62–$575 $164
2025 $3,205 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $2,926 103 payments
  2. AbbVie, Inc. $2,422 84 payments
  3. Janssen Biotech, Inc. $1,869 128 payments
  4. UCB, Inc. $1,824 66 payments
  5. AstraZeneca Pharmaceuticals LP $1,287 40 payments
  6. GlaxoSmithKline, LLC. $1,023 41 payments
  7. Horizon Therapeutics plc $919 31 payments
  8. Pfizer Inc. $848 64 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $592 15 payments
  10. Genentech USA, Inc. $378 19 payments
  11. Other $2,578 98 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,387 684 payments
  2. Education $278 5 payments
Products named General payments · program years 2021–2025
  1. SIMPONI ARIA $1,764 119 payments
  2. RINVOQ $1,692 55 payments
  3. SAPHNELO $1,121 37 payments
  4. TREMFYA $1,056 50 payments
  5. BENLYSTA $1,023 41 payments
  6. Cimzia $934 41 payments
  7. Bimzelx $890 25 payments
  8. Otezla $871 34 payments
  9. KRYSTEXXA $858 24 payments
  10. XELJANZ $796 61 payments
  11. Other $8,584 448 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

4,484

Median for Nurse Practitioner: 389

Drug cost

$2,651,114

Median for Nurse Practitioner: $21,885

Branded share of claims

35.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 35 $401,508
Enbrel Sureclick Etanercept Brand 43 $322,038
Actemra Tocilizumab Brand 69 $282,580
Xeljanz Xr Tofacitinib Citrate Brand 43 $242,097
Otezla Apremilast Brand 37 $234,758
Actemra Actpen Tocilizumab Brand 49 $212,077
Rinvoq Upadacitinib Brand 28 $202,238
Orencia Abatacept/Maltose Brand 22 $165,890
Orencia Clickject Abatacept Brand 27 $156,839
Kevzara Sarilumab Brand 33 $136,417

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$74,571

Of which drugs: $54,735

Medicare patients

194

Average age 72

Services billed

5,867

131 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 31%
Chronic kidney disease 31%
Osteoporosis 30%
Depression 24%
COPD 22%
Ischemic heart disease 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 14 1,280 $128
Injection, methylprednisolone acetate, 40 mg J1030 Office 11 17 $45

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $437
$437 28 —
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $279
$279 — —
XELJANZ
  • PFIZER INC. $253
$253 43 —
Cimzia
  • UCB, Inc. $247
$247 12 —
TREMFYA
  • Janssen Biotech, Inc. $238
$238 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

689 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record